Summary
GlobalData, the industry analysis specialist's new report, "Asthma-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global asthma market. The report identifies the key trends shaping and driving the global asthma market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global asthma sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global asthma market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
-Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global asthma market.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with asthma.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global asthma market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global asthma market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global asthma market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Global Asthma Market: Market Characterization 6
2.1 Overview 6
2.2 Asthma Market Size 6
2.3 Asthma Market Forecast and CAGR 6
2.4 Drivers and Barriers for Asthma Market 7
2.4.1 Drivers for Asthma Market 8
2.4.2 Barriers for Asthma Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Asthma Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in Asthma Market 12
3.3.1 Singulair (montekeulast sodium) 12
3.3.2 Accolate (zafirlukast, Accoleit, Vanticon) 13
3.3.3 Zyflo (zileuton) 14
3.3.4 Foradil (formoterol fumarate inhalation powder) 15
3.3.5 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 17
3.3.6 Xolair (omalizumab) 18
3.3.7 Serevent Diskus (salmaterol xinafoate inhalation powder) 20
3.3.8 Advair Diskus (fluticasone propionate and salmeterol inhalation powder) 21
3.4 Key Takeaway 26
4 Asthma Market: Pipeline Assessment 27
4.1 Overview 27
4.2 Strategic Pipeline Assessment 27
4.2.1 Technology Trends Analytic Framework 27
4.3 Asthma Therapeutics-Promising Drugs under Clinical Development 29
4.4 Molecule Profile for Promising Drugs for Asthma under Clinical Development 31
4.4.1 Flutiform (fluticasone propionate/formoterol fumarate inhalation aerosol) 31
4.4.2 MFF 258 (Mometasone furoate/formoterol fumarate) 32
4.4.3 Roflumilast (Daxas, APTA 2217, B9302-107, BY 217, BYK 20869) 33
4.4.4 GSK159797/642444, Beyond Advair 34
4.4.5 QMF149 (Mometasone/indacaterol) 34
4.4.6 Oglemilast 35
4.4.7 LAS100977 36
4.4.8 Bosatria (SB-240563) (Mepolimuzab) 36
4.4.9 Aerovant (AER001, pitrakinra) 37
4.5 Asthma Therapeutics Market-Clinical Pipeline by Mechanism of Action 38
4.6 Asthma Pipeline-Pipeline by Clinical Phases of Development 39
4.6.1 Asthma Therapeutics-Phase III Clinical Pipeline 40
4.6.2 Asthma Therapeutics-Phase II Clinical Pipeline 40
4.6.3 Asthma Therapeutics-Phase I Clinical Pipeline 42
4.6.4 Asthma Therapeutics-Preclinical Pipeline 44
4.6.5 Asthma Therapeutics-Discovery Pipeline 45
4.7 Discontinued/Suspended Drug for Asthma 45
4.8 Key Takeaway 51
5 Asthma Market: Implications for Future Market Competition 52
6 Asthma Market: Future Players in the Asthma Market 54
6.1 Introduction 54
6.1.1 SkyePharma PLC. 54
6.1.2 Respiratory Disease Portfolio 55
6.1.3 Asthma Product Portfolio 55
6.2 Schering-Plough Corporation 57
6.2.1 Overview 57
6.2.2 Respiratory Disease Portfolio 58
6.2.3 Asthma Product Portfolio 58
6.3 Altana Pharmaceuticals 60
6.3.1 Overview 60
6.3.2 Respiratory Disease Portfolio 60
6.3.3 Asthma Product Portfolio 60
6.4 GlaxoSmithKline plc. 61
6.4.1 Overview 61
6.4.2 Respiratory Disease Portfolio 62
6.4.3 Asthma Product Portfolio 63
6.5 Glenmark 66
6.5.1 Overview 66
6.5.2 Respiratory Disease Portfolio 67
6.5.3 Asthma Product Portfolio 67
6.6 Almirall S.A 67
6.6.1 Overview 67
6.6.2 Respiratory Disease Portfolio 68
6.6.3 Asthma Product Portfolio 68
6.7 Aerovance Inc. 69
6.7.1 Overview 69
6.7.2 Asthma Product Portfolio 69
6.8 Theravance, Inc. 70
6.8.1 Overview 70
6.8.2 Asthma Product Portfolio 71
7 Asthma Market: Appendix 72
7.1 Market Definitions 72
7.2 Abbreviations 72
7.3 Research Methodology 73
7.3.1 Coverage 73
7.3.2 Secondary Research 74
7.3.3 Forecasting 74
7.3.4 Primary Research 77
7.3.5 Expert Panel validation 77
7.4 Contact Us 77
7.5 Disclaimer 77
7.6 Sources 78

List of Tables
1.1 List of Tables
Table 1: Global Asthma Therapeutics Market, Revenue Forecasts ($bn), 2001-2009 7
Table 2: Global Asthma Therapeutics Market, Revenue Forecasts ($bn), 2009-2016 7
Table 3: Major Marketed Products Comparison in the Asthma Market, 2010 23
Table 4: Asthma Therapeutics-Most Promising Drugs Under Clinical Development, 201 29
Table 5: Asthma Therapeutics-Phase III Clinical Pipeline, 2010 40
Table 6: Asthma Therapeutics-Phase II Clinical Pipeline, 2010 40
Table 7: Asthma Therapeutics-Phase I Clinical Pipeline, 2010 42
Table 8: Asthma Therapeutics-Preclinical Pipeline, 2010 44
Table 9: Asthma Therapeutics-Discovery Pipeline, 2010 45
Table 10:     List of Discontinued Drugs for Asthma, 2010 45
Table 11: Skye Pharma-Respiratory Pipeline Products, 2010 55
Table 12: Schering-Plough-Respiratory Pipeline Products, 2010 58
Table 13: Altana Pharmaceuticals-Respiratory Disease Pipeline Products, 2010 60
Table 14: GlaxoSmithKline plc-Respiratory Disease Pipeline Products, 2010 62
Table 15: Glenmark Pharmaceuticals Limited-Respiratory Disease Pipeline Products, 2010 67
Table 16: Almirall S.A-Respiratory Disease Pipeline Products, 2010 68
Table 17: Aerovance Inc.-Respiratory Disease Pipeline Products, 2010 69
Table 18: Theravance, Inc.-Respiratory Disease Pipeline Products, 2010 70

List of Figures
1.2 List of Figures
Figure 1: Global Asthma Therapeutics Market, Revenue ($bn), 2001-2009 6
Figure 2:    Global Asthma Market Revenue ($bn), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Asthma Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Asthma, 2010 12
Figure 5: Technology Trends Analytic Framework of the Asthma Pipeline, 2010 27
Figure 6: Technology Trends Analytic Framework  of the Asthma Pipeline-Description, 2010 28
Figure 7:    Asthma Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 39
Figure 8: Asthma Pipeline by Phase of Clinical Development, 2010 39
Figure 9: Implications for Future Market Competition in the Asthma Market, 2010 52
Figure 10: Asthma Therapeutics Market-Clinical Pipeline by Company, 2010 54
Figure 11: GlobalData Methodology 73
Figure 12: GlobalData Market Forecasting Model 76